Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following ...
BV500: Entered global research collaboration with Shionogi for broad-spectrum non-tuberculous mycobacteria Successful IPO funding operations into 2028 with BV100 Phase 3 read-out by the end of 2027 ...
Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026. La Food and Drug Administration (FDA) des États-Unis a a ...
157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au refinancement réussi de la dette ; réduction de 21% de la cons ...
Ipsen est coté à Paris (Euronext : IPN) et aux Etats-Unis à travers un programme d’American Depositary Receipt (ADR : IPSEY) sponsorisé de niveau I. Pour plus d’informations, consultez ipsen.com/fr/.
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ; ...
As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the CyberMega Smart Treadmill across ...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease. Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Bre ...
CytomX expects to use the net proceeds from this offering for the continued development of Varseta-M and other pipeline programs. CytomX expects to use any remaining net proceeds from this offering ...
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune ...
A 2026 company-issued informational report covering NatureGlyco's product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results